Advances in the role of lysophosphatidyl-choline acyltransferase 1 in tumors

doi:10.16352/j.issn.1001-6325.2024.02.0256

Abstract

Abstract: Lysophosphatidylcholine acyltransferase 1(LPCAT1), a key metabolic enzyme in the phosphatidyl-choline metabolism pathway, mediates phosphatidylcholine synthesis through deacylation-reacylation, which leads to alterations in the phospholipids composition of cell membranes and the remodelling of the cellular cytoskeleton. Lysophosphatidylcholine acyltransferase 1 has been shown to be highly expressed in gastric, breast and colorectal cancer, and can accelerate the alteration of the phospholipids composition of tumor cell membranes or interact with tumor driver genes, such as epidermal growth factor receptor and cell cycle-related genes. It might promote tumor development by affecting tumor cell proliferation, migration, invasion and resistance to chemotherapy.

Key words: lysophosphatidylcholine acyltransferase 1(LPCAT1), phosphatidylcholine metabolism, phospholipids, tumor

CLC Number:

R730.23

CHEN Xue, LUO Tian, WEI Chaojun. Advances in the role of lysophosphatidyl-choline acyltransferase 1 in tumors[J]. Basic & Clinical Medicine, 2024, 44(2): 256-259.

References

[1]Balleza D, Alessandrini A, Beltrán García MJ. Role of lipid composition, physicochemical interactions, and membrane mechanics in the molecular actions of microbial cyclic lipopeptides[J]. J Membr Biol, 2019, 252:131-157.
[2]Johnson AA, Stolzing A. The role of lipid metabolism in aging, lifespan regulation, and age-related disease[J]. Aging cell, 2019, 18:e13048. doi: 10.1111/acel.13048.
[3]Butnor KJ. Controversies and challenges in the histologic subtyping of lung adenocarcinoma[J]. Transl Lung Cancer Res, 2020, 9:839-846.
[4]Szlasa W, Zendran I, Zalesińska A, et al. Lipid composition of the cancer cell membrane[J]. J Bioenerg Biomembr, 2020, 52:321-342.
[5]Chen ZX, Liang L, Huang HQ, et al. LPCAT1 enhances the invasion and migration in gastric cancer: based on computational biology methods and in vitro experiments[J]. Cancer Med, 2023,12:13438-13454.
[6]Bi J, Ichu TA, Zanca C, et al. Oncogene amplification in growth factor signaling pathways renders cancers depend-ent on membrane lipid remodeling[J]. Cell Metab, 2019, 30:525-538.e8.
[7]Ji W, Peng Z, Sun B, et al. Lpcat1 promotes malignant transformation of hepatocellular carcinoma cells by directly suppressing STAT1[J]. Front Oncol, 2021, 11:678714.doi: 10.3389/fonc.2021.678714.
[8]Liu Y, Yang C, Zhang Z, et al. Gut microbiota dysbiosis accelerates prostate cancer progression through increased LPCAT1 expression and enhanced DNA repair pathways[J]. Front Oncol, 2021, 11:679712.doi: 10.3389/fonc.2021.679712.
[9]Oliver GR, Marcano-Bonilla S, Quist J, et al. LPCAT1-TERT fusions are uniquely recurrent in epithelioid trophoblastic tumors and positively regulate cell growth[J]. PLoS One, 2021, 16:e0250518.doi: 10.1371/journal.pone.0250518.
[10]Tao M, Luo J, Gu T, et al. LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma[J]. Cell Death Dis, 2021, 12:845. doi: 10.1038/s41419-021-04132-6.
[11]Shen L, Gu P, Qiu C, et al. Lysophosphatidylcholine acyltransferase 1 promotes epithelial-mesenchymal transi-tion of hepatocellular carcinoma via the Wnt/β-catenin signaling pathway[J]. Ann Hepatol, 2022, 27:100680. doi: 10.1016/j.aohep.2022.100680.
[12]Liu R, Yin C, Zhao P, et al. Nuclear respiratory factor 1 drives hepatocellular carcinoma progression by forming a positive feedback loop with LPCAT1-ERK1/2-CREB axis[J]. Biol Direct, 2023,18:67. doi: 10.1186/s13062-023-00428-z.
[13]Wei C, Dong X, Lu H, et al. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway[J]. Clin Cancer Res, 2019, 38:95. doi: 10.1186/s13046-019-1092-4.
[14]Zhao T, Sun R, Ma X, et al. Overexpression of LPCAT1 enhances endometrial cancer stemness and metastasis by changing lipid components and activating the TGF/β-Smad2/3 signaling pathway[J]. Acta Biochim Biophys Sin (Shanghai), 2022, 54:904-916.
[15]Ding J, Ding X, Leng Z. LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signal-ing pathway in lung adenocarcinoma[J]. J Cancer, 2022, 13:1837-1847.
[16]Jun Y, Tang Z, Luo C, et al. Leukocyte-mediated combined targeted chemo and gene therapy for esophageal cancer[J]. ACS Appl Mater Interfaces, 2020, 12:47330-47341.
[17]Zhang H, Zheng Y. LPCAT1 is transcriptionally regulated by FOXA1 to promote breast cancer progression and paclitaxel resistance[J]. Oncol Lett, 2023, 25:134.doi: 10.3892/ol.2023.13720.